Salivary toxicity from PSMA-targeted radiopharmaceuticals: What we have learned and where we are going

Salivary toxicity is an exceptionally common side effect of PSMA-targeted radiopharmaceuticals. In VISION, a phase III registrational trial for [177Lu]Lu-PSMA-617, the observed rate of grade 1 or 2 dry mouth was 39  % [1]. In a post-hoc exposure-adjusted analysis accounting for longer safety observation time, the adjusted incidence of any grade dry mouth was remarkably high at 75.1 per 100 patient treatment-years (PTY) [2]. Similar results have been reported in other large trials of [177Lu]Lu-PSMA-617.

Source: Cancer Treatment Reviews - April 29, 2024 Category: Cancer & Oncology Authors: Miguel Muniz, Charles L Loprinzi, Jacob J Orme, Regina M Koch, Ahmed M Mahmoud, Adam M Kase, Irbaz B Riaz, Jack R Andrews, Matthew P Thorpe, Geoffrey B Johnson, Ayse T Kendi, Eugene D Kwon, Jones T Nauseef, Alicia K Morgans, Oliver Sartor, Daniel S Childs Tags: General and Supportive Care Source Type: research